New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review process in terms ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atara (ATRA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Atara securities between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar E ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates Accessibility StatementSkip NavigationTheravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS EnrollmentNEW YORK, March 25, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encourage ...

Philadelphia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Power Solutions International, Inc. (NASDAQ: PSIX) ("Power Solutions" or the "Company") on behalf of investors who purchased or acquired Power Solutions shares during the period from May 8, 2025 through March 2, 2026 (the "Class Period").Investor Deadline: Investors who purchased or acquired Power Solutions securities during the Class Period may, no later ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Stellantis N.V. (“Stellantis” or the “Company”) (NYSE: STLA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 6, 2026, Stellantis “announced that as part of the reset of its business and as it prepares for the ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financ ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Coty Inc. (“Coty” or the “Company”) (NYSE: COTY) between November 5, 2025, and February 4, 2026, inclusive. You are hereby notified that the class action lawsuit Suvega Srinivasan v. Coty Inc., et al. (Case No. 1:26-cv-02343) has been commenced in the United States District Court for the Southern District of New York. T ...

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to its lead pipeline candidate, Seralutinib, and the PROSERA study results [1][4]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2]. - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

RADNOR, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by GoDaddy Inc. (GoDaddy) (NYSE: GDDY) on behalf of investors who purchased or acquired GDDY securities and experienced significant financial losses. GoDaddy Reports Disappointing Financial Results On February 24, 2026, GoDaddy reported disappointing fourth quarter 2025 financial results. ...